​

Rallybio (RLYB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

RLYB Stock Rating

Rallybio stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (50.00%), 4 Hold (50.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 4 4 Strong Sell Sell Hold Buy Strong Buy

RLYB Price Target Upside V Benchmarks

TypeNameUpside
StockRallybio-
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$9.41$9.41$9.41
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26-13--4
Feb, 26-13--4
Jan, 26-13--4
Dec, 25-13--4
Nov, 25-13--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 01, 2024H.C. WainwrightBuyBuyhold
Sep 03, 2024H.C. WainwrightBuyBuyhold
Feb 22, 2022JMP SecuritiesMarket Outperforminitialise

Financial Forecast

EPS Forecast

$-15 $-11 $-7 $-3 $1 $5 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-14.72$-10.64$-1.59---
Avg Forecast$-1.79$-1.42$-1.32$-2.73$0.19$4.64
High Forecast$-1.69$-1.40$-1.15$-2.73$0.19$4.64
Low Forecast$-1.85$-1.44$-1.48$-2.73$0.19$4.64
Surprise %722.35%649.30%20.45%---

Revenue Forecast

$50M $120M $190M $260M $330M $400M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$636.00K$858.00K---
Avg Forecast-$673.75K$305.00K-$87.90M$388.10M
High Forecast-$673.75K$305.00K-$87.90M$388.10M
Low Forecast-$673.75K$305.00K-$87.90M$388.10M
Surprise %--5.60%181.31%---

Net Income Forecast

$-150M $-80M $-10M $60M $130M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-74.56M$-57.77M$-8.98M---
Avg Forecast$-74.56M$-57.44M$-49.20M$-110.42M$7.69M$187.68M
High Forecast$-68.46M$-56.58M$-46.60M$-110.42M$7.69M$187.68M
Low Forecast$-74.94M$-58.29M$-59.85M$-110.42M$7.69M$187.68M
Surprise %-0.59%-81.75%---

RLYB Forecast FAQ

Is Rallybio stock a buy?

Rallybio stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Rallybio is a favorable investment for most analysts.

What is Rallybio's price target?

Rallybio's price target, set by 8 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $9.41.

How does Rallybio stock forecast compare to its benchmarks?

Rallybio's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Rallybio over the past three months?

  • March 2026: 0% Strong Buy, 25.00% Buy, 75.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 25.00% Buy, 75.00% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 0% Strong Buy, 25.00% Buy, 75.00% Hold, 0% Sell, 0% Strong Sell.

What is Rallybio’s EPS forecast?

Rallybio's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.73, marking a 71.70% increase from the reported $-1.59 in 2025. Estimates for the following years are $0.19 in 2027, and $4.64 in 2028.

What is Rallybio’s revenue forecast?

Rallybio's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a -100.00% decrease from the reported $858K in 2025. The forecast for 2027 is $87.9M, and $388.1M for 2028.

What is Rallybio’s net income forecast?

Rallybio's net income forecast for the fiscal year ending in December 2026 stands at $-110M, representing an 1129.91% increase from the reported $-8.978M in 2025. Projections indicate $7.69M in 2027, and $187.68M in 2028.